GlassScriptPhysician profile
Harry H Yoon
NPI 1255408258
$69,013.52
in general payments reported to CMS, 2019-2025
13 companies · $7,676 in 2025
The $7,676 reported for 2025 was more than what 78% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $6,790 · 2021: $4,749 · 2022: $15K · 2023: $3,965 · 2024: $15K · 2025: $7,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,098 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $208 · Travel and Lodging: $142 · Food and Beverage: $79.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,847.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,097.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $208.31 |
| Travel and Lodging | $141.50 |
| Food and Beverage | $79.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29,791.75 | 2019-2024 | Keytruda |
| Beigene USA, INC. | $14,107.26 | 2022-2024 | Tevimbra |
| Daiichi Sankyo INC. | $4,908.45 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $4,050.00 | 2020 | |
| Jazz Pharmaceuticals INC. | $3,097.50 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $2,875.01 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $2,625.00 | 2021-2022 | |
| Beone Medicines USA, INC. | $2,200.00 | 2025 | Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $2,100.00 | 2025 | |
| Astellas Pharma US INC | $2,061.25 | 2021 | |
| Amgen INC. | $973.50 | 2022 | |
| Taiho Oncology, INC. | $223.80 | 2024-2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.